Company intelligence / Profile preview

Immunicom, Inc.

San Diego, California, United Statesimmunicom.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Worldwide clinical trials are underway at leading hospitals to evaluate Immunopheresis in several cancer types, both as a singular therapy and in combination with other treatments. Recently received $2 million from NCI/NIH to initiate clinical trial for refractory ER+/Her2- Breast Cancer[1].

Therapeutic areas: OncologyImmunologyNephrology
Modalities: Medical device-based immunotherapyExtracorporeal therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

LW-02

Phase 2

Indications: Triple-negative breast cancer

Partnerships

Terumo BCT (uses their Spectra Optia® centrifugal plasma separator)[5]

Beyond the preview

Go deeper on Immunicom, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunicom, Inc..

Explore the full profile